SCOT Registry: Small Cell Lung Cancer Treatment and Outcome

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Lung Cancer, Small Cell

Treatments: Drug: HYCAMTIN

Study type: Observational

Funder types: Industry

Identifiers

NCT00997061

112791

Details and patient eligibility

About

The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC.

Data will be entered into an electronic CRF (eCRF) via Internet access. Treatment plan remains the responsibility of the patient's physician and data collected in this registry will reflect a "real world" approach of the diagnosis and treatment of patients with SCLC.

Approximately 60 centres in 13 countries will take part in this registry. It is expected that about 500 patients will be recruited during a period of 6 to 9 months according to the feasibility.

Enrollment: 500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female >/= 18 years
• Diagnosis of small cell lung cancer
• Patient newly diagnosed with SCLC
• Has given written informed consent (if applicable)

Exclusion criteria

• Concurrent history of other neoplasm, except curatively treated basal cell skin cancer or adequately treated in-situ carcinoma of the cervix.
• Patient presenting with recurrence of SCLC.
• Patients who has received any chemotherapy for the SCLC.

Trial design

500 participants in 1 patient group

HYCAMTIN

Treatment:

Drug: HYCAMTIN